These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 24628640)

  • 21. Induction of depression with oxotremorine in patients with Alzheimer's disease.
    Davis KL; Hollander E; Davidson M; Davis BM; Mohs RC; Horvath TB
    Am J Psychiatry; 1987 Apr; 144(4):468-71. PubMed ID: 3565616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early amelioration of insulin resistance and reduction of interleukin-6 in Werner syndrome using pioglitazone.
    Honjo S; Yokote K; Fujishiro T; Maezawa Y; Sato S; Koshizaka M; Saito Y
    J Am Geriatr Soc; 2008 Jan; 56(1):173-4. PubMed ID: 18184212
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's Disease, time to turn the tide.
    Sensi SL
    Aging (Albany NY); 2018 Oct; 10(10):2537-2538. PubMed ID: 30317224
    [No Abstract]   [Full Text] [Related]  

  • 25. Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.
    Léger GC; Massoud F
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):423-42. PubMed ID: 23927670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Variability of efficacy measures in Alzheimer's disease].
    Musicco M; Pettenati C; Caltagirone C
    Ann Ist Super Sanita; 2005; 41(1):87-91. PubMed ID: 16037656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease.
    Duron E; Rigaud AS; Dubail D; Mehrabian S; Latour F; Seux ML; Hanon O
    Am J Hypertens; 2009 Sep; 22(9):1020-4. PubMed ID: 19590498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
    Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
    Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wesnes K; Edgar C; Andreasen N; Annas P; Basun H; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Oct; 122(4):270-7. PubMed ID: 20047570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is antidepressant treatment associated with reduced cognitive decline in Alzheimer's disease?
    Mossello E; Boncinelli M; Caleri V; Cavallini MC; Palermo E; Di Bari M; Tilli S; Sarcone E; Simoni D; Biagini CA; Masotti G; Marchionni N
    Dement Geriatr Cogn Disord; 2008; 25(4):372-9. PubMed ID: 18354253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgens and Alzheimer's disease.
    Drummond ES; Harvey AR; Martins RN
    Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):254-9. PubMed ID: 19373081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Research design issues: antialuminum drug studies in Alzheimer's disease.
    Shore D; Wyatt RJ
    Clin Neuropharmacol; 1982 Dec; 5(4):337-43. PubMed ID: 7159877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.
    Farlow MR; Cummings JL; Olin JT; Meng X
    Am J Alzheimers Dis Other Demen; 2010 Jun; 25(4):347-52. PubMed ID: 20392862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the effects of memantine on clinical progression in Alzheimer's disease.
    Wilkinson D
    Int J Geriatr Psychiatry; 2012 Aug; 27(8):769-76. PubMed ID: 21964871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's disease: cognitive and behavioral pharmacotherapy.
    Cummings JL; Mendez MF
    Conn Med; 1997 Sep; 61(9):543-52. PubMed ID: 9334509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of phosphatidylserine in Alzheimer's disease.
    Amaducci L; Crook TH; Lippi A; Bracco L; Baldereschi M; Latorraca S; Piersanti P; Tesco G; Sorbi S
    Ann N Y Acad Sci; 1991; 640():245-9. PubMed ID: 1776745
    [No Abstract]   [Full Text] [Related]  

  • 40. NSAIDs and cognition in Alzheimer's disease.
    Doraiswamy PM; Krishen A; Stallone F; Martin WL; Potts NL; Metz A; MRCPsych AM; DeVeaugh-Geiss J
    Neurology; 1996 Apr; 46(4):1194. PubMed ID: 8780138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.